BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21958544)

  • 1. Indolin-2-one p38α inhibitors III: bioisosteric amide replacement.
    Eastwood P; González J; Gómez E; Caturla F; Aguilar N; Mir M; Aiguadé J; Matassa V; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6253-7. PubMed ID: 21958544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amide-based inhibitors of p38alpha MAP kinase. Part 1: discovery of novel N-pyridyl amide lead molecules.
    Luedtke GR; Schinzel K; Tan X; Tester RW; Nashashibi I; Xu YJ; Dugar S; Levy DE; Jung J
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2556-9. PubMed ID: 20346653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
    Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
    Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.
    Mavunkel BJ; Perumattam JJ; Tan X; Luedtke GR; Lu Q; Lim D; Kizer D; Dugar S; Chakravarty S; Xu YJ; Jung J; Liclican A; Levy DE; Tabora J
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1059-62. PubMed ID: 20031411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides.
    Tester R; Tan X; Luedtke GR; Nashashibi I; Schinzel K; Liang W; Jung J; Dugar S; Liclican A; Tabora J; Levy DE; Do S
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2560-3. PubMed ID: 20346659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
    Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
    Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
    J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted isoxazoles as potent inhibitors of p38 MAP kinase.
    Laufer SA; Margutti S; Fritz MD
    ChemMedChem; 2006 Feb; 1(2):197-207. PubMed ID: 16892352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
    Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indolin-2-one p38α inhibitors II: Lead optimisation.
    Eastwood P; González J; Gómez E; Caturla F; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5270-3. PubMed ID: 21813275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.